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Abstract
The extracellular matrix is the intricate scaffolding which surrounds and supports cells
and helps to organize them into tissues and organs. The CCN family of matricellular
proteins helps to regulate and modulate production, degradation, and remodeling of
the extracellular matrix. In this chapter, we review the extracellular matrix of cartilage
and bone, including an overview of chondrogenesis and skeletogenesis, and summa‐
rize the importance of the CCN proteins in establishment of the skeletal system. CCN
proteins have both positive and negative regulatory roles in skeletal development, and
their abnormal expression is related to the pathogenesis of several diseases observed in
cartilage and bone that arise when inflammation or tissue injury becomes chronic,
including fibrosis, arthritis, and cancer. Understanding the biological functions of the
CCN proteins within this context offers opportunities for developing therapeutics by
targeting CCN functions.
Keywords: matricellular proteins, CCN family, chondrogenesis; osteogenesis, extra-
cellular matrix
1. Introduction
The extracellular matrix (ECM) is the intricate scaffolding, which surrounds and supports cells,
and helps to organize them into tissues and organs. The composition of the extracellular matrix
varies based on tissue type and organ function, and this matrix affects many cellular behav‐
iors including proliferation, differentiation, and wound healing. Matricellular proteins, present
in the immediate environment of the cell, help to regulate and modulate these functions. We
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present a discussion of the important matrix elements of cartilage and bone, and the support‐
ing connective tissues of the body, with regard to their function in health and disease. The major
aim of this book chapter is to summarize the role of extracellular matrix proteins and their roles
in chondrogenesis and osteogenesis. Additionally, we will discuss the importance of the CCN
proteins—a family of secreted extracellular matrix‐associated proteins—in functional path‐
ways of chondrogenesis and osteogenesis, and include a discussion of the role of CCNs in
pathophysiology of these tissues. The reader will gain an increased awareness of the impor‐
tance of CCN proteins in a wide range of important functional pathways, providing in‐depth
focus on their role in bone and cartilage development and repair. These proteins have also been
implicated in many human diseases and thus are important targets for drug discovery and
development.
2. Overview of chondrogenesis
Cartilage is a specialized type of supporting connective tissue that contains cartilage cells, or
chondrocytes, and a specialized extracellular matrix. The type of matrix is specific to the type
of cartilage. Depending on the type of cartilage, there may be a perichondrium present, which
is a connective tissue layer that contains mesenchymal cells or fibroblasts, as well as chon‐
droblasts. Cartilage develops from mesenchyme cells that commit to become chondrocytes.
Cartilage is first seen in the developing embryo in the areas that serve as templates for
endochondral ossification, as well as in Meckel's cartilage in the head area [1]. Differentiated
chondrocytes are surrounded by matrix and can appear to have space around them and they
retain their proliferative capacity within their matrix. Development of cartilage involves
several different transcription factors, such as Sox 9, that control this process, as well as growth
factors that interact with cellular receptors to facilitate various cellular functions [2]. Interac‐
tion with the extracellular matrix has been implicated in development as well. Various
epigenetic mechanisms and several different microRNAs also are important in the develop‐
ment of cartilage [3,4]. Chondrocytes may remain as cartilage in specific regions of the body
or may be used as a template for the formation of many of the bones in the body during
endochondral ossification. Cartilage remains in the adult in several specific places including
the bridge of the nose, the trachea and bronchi, the ear, the intervertebral discs of the spinal
column, and on the ends of bones as articular cartilage [5]. Chondrocytes are usually consid‐
ered quiescent in the adult, although this can change during pathological processes such as
osteoarthritis. Cartilage has very little capacity to regenerate, even though progenitor cells are
present in the adult [6]. This lack of repair ability causes a number of disease issues as humans
age, including the most prevalent form of degenerative joint disease, osteoarthritis [7].
2.1. Types of cartilage
Three kinds of cartilage have been identified: hyaline, elastic, and fibrous based on differences
in matrix and cellular arrangement and function [5,8]. Hyaline is present in the bronchi, parts
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of the trachea, and also as articular cartilage. It also forms the model for bone formation during
endochondral ossification. Another elastic cartilage is present in the oropharynx and ear,
among other regions of the body. Both of these types of cartilage are typically surrounded by
a connective tissue layer and a chondrogenic layer of the perichondrium. Cells from this layer
can undergo proliferation and can differentiate into chondrocytes for growth or renewal of
cartilage, a type of growth that is appositional in that the newly formed chondrocytes come
from outside the cartilage matrix. In addition, cells within the cartilage can proliferate, forming
isogenous groups of similar chondrocytes, which is termed interstitial growth. By contrast,
articular cartilage, at the surface, is not covered by a perichondrium. This lack of a perichon‐
drium results in the proliferation of articular cartilage occurring only from within the matrix
itself. An unfortunate consequence of this lack of a perichondrium is that the articular cartilage,
continually exposed to stress from the movement of the joint, is less able to repair itself since
no proliferation can occur from the perichondrium. Aging also leads to decreased healing
ability and thus damage to cartilage may not repair sufficiently to prevent disease [9]. Damage
to the articular cartilage leads to the most common [10] affliction of the aging population,
osteoarthritis.
The third type of cartilage, fibrocartilage, is present as a transitional tissue generally connecting
two other structures or tissues. Fibrocartilage does not have a perichondrium and thus only
grows interstitially. Due to stress on this cartilage, the chondrocytes are typically arranged in
a linear fashion [5]. One prominent place where fibrocartilage is present is in the annulus
fibrosus of intervertebral discs. It is present in other areas such as part of the knee joint as well.
Damage to this tissue may lead to herniation of the intervertebral disc, another major health
issue as this may cause back pain [11].
Chondrocytes are surrounded by a thin pericellular matrix containing specific proteins, termed
matricellular proteins, which have significantly different properties than the majority of the
cartilage matrix [12]. This matrix and the associated chondrocyte are termed a chondron [13].
The matricellular proteins may confer the ability to withstand degradation by matrix metal‐
loproteinases (MMPs), and this may be due to the localization of type VI collagen in this region
[14,15]. This collagen is not broken down by many matrix metalloproteinases. Surrounding
the pericellular matrix is the matrix termed histologically the territorial matrix and in between
groups of chondrocytes is the interterritorial matrix [5].
3. Overview of skeletogenesis
The skeletal system is primarily composed of bone and cartilage, both mesodermal‐derived
tissues formed through the differentiation and cellular function of osteoblasts and chondro‐
cytes. Skeletogenesis is a complex, multistep process involving the coordinated actions of
osteoblast gene expression and cellular activity that are regulated by a multitude of systemic
and locally produced growth factors, as well as complex extracellular matrix interaction [16].
Osteoblasts are highly differentiated bone lining cells responsible for the production of bone
through secretion and mineralization of ECM constituents. Osteoblasts are protein‐producing
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cells characterized morphologically by a round nucleus, an intensely basophilic cytoplasm, a
prominent Golgi complex, and a well‐developed rough endoplasmic reticulum. Osteoblast
precursors originate from local pluripotent mesenchymal stem cells from the bone marrow
stromal mesenchymal stem cells. Under specific conditions, including ECM interactions,
osteoblast precursors will proliferate and differentiate into pre‐osteoblasts cells that are
committed to differentiate into mature osteoblasts [16–18]. The majority of these mature
synthetic osteoblasts will become osteocytes as they become embedded in their secreted ECM.
Osteocytes are the most abundant cell type in the bone and have the ability to resorb and
synthesize bone matrix but in a more limited capacity compared to osteoclasts and osteoblasts,
respectively [19]. These osteocytes form an interconnected network called the lacunocanalic‐
ular system that is embedded within the mineralized tissue. The matrix directly surrounding
the lacunocanalicular system is not mineralized and has fluid‐like mechanical properties and
contains ECM proteins secreted by osteocytes [20]. This system is thought to play an active
role in bone remodeling and adaptation by sensing and responding to biomechanical and other
systemic stimuli. In addition, the ECM proteins produced here also play a role in mineraliza‐
tion [21,22]. Osteoclasts are bone‐lining cells that are responsible for bone resorption. Osteo‐
clasts are characterized morphologically as very large, multinucleated cell with abundant
Golgi complexes and numerous transport vesicles loaded with lysosomal enzymes. The zone
of contact with bone is characterized by the presence of a ruffled border where bone resorption
takes place [16,18]. Osteoclasts originate from hematopoietic precursors of the mononuclear/
phagocytic lineage that are capable of multilineage differentiation as well as self‐renewal.
Thus, skeletogenesis results from the total contribution of all of these cell types and occurs as
the result of two distinct processes in vivo: endochondral and intramembranous ossification.
3.1. Intramembranous ossification
Intramembranous ossification occurs in the flat skull bones and the clavicle and involves the
condensation and direct differentiation of osteochondral progenitors into bone‐forming
osteoblasts [23]. The process begins with mesenchymal cell proliferation and condensation
into compact nodules at the future sites of bone formation. As these condensations begin to
form, mesenchymal cells within the interior of these nodules stop replicating and undergo
changes in gene expression (i.e., Runx2/Cfba 1; Osx) [24,25] and associated morphological
changes that are characteristic of osteoprogenitor cells. These osteoprogenitor cells begin to
secrete a collagen‐proteoglycan, pre‐bone matrix termed osteoid that eventually becomes
mineralized through deposits of minerals such as calcium and phosphates. Typically, osteo‐
blasts remain separated from this mineralized matrix by a layer of the osteoid matrix they
secrete; however, some osteoblasts remain trapped in this mineral matrix and become
osteocytes. As this process proceeds further, bony spicules are formed and begin to radiate
from the region where ossification began. Compacted mesenchymal cells on the exterior of
these nascent bony spicules also begin to form a dense layer of vascularized connective tissue
that surrounds the mineralized tissue to form the periosteum. The periosteum consists of two
primary histological layers: a fibrous layer that has dense collagenous tissue and a cambium
layer that is cellular and functions to provide osteoblast cells during bone expansion, regen‐
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eration, and fracture repair [26–28]. The cells that remain on the inner surface of the periosteum
also differentiate into osteoblasts and deposit osteoid matrix parallel to that of the existing
spicules forming bone layers.
3.2. Endochondral ossification
Endochondral ossification occurs for most axial and appendicular bones (e.g., long bones)
and involves the differentiation of osteochondral progenitors into chondrocytes that form a
cartilage template (anlagen) that will eventually be transformed into bone tissue [23]. Endo‐
chondral ossification also begins with condensations of mesenchymal stem cells that migrate
to the site of future bone formation and resemble the eventual shape of the bone that will be
formed [29]. The distinction between intramembranous and endochondral bone formation
lies in the fact that the mesenchymal cells found within the interior of these condensations
express cartilage‐specific genes [30,31] and differentiate into chondrocytes to form cartilagi‐
nous models. N‐cadherin appears to be important in the initiation of these condensations,
and N‐CAM also seems to be critical for their maintenance [32,33]. These chondrocytes also
secrete collagen II, aggrecan, and other matrix molecules that constitute the ECM of hyaline
cartilage [29]. As development proceeds, further chondrocyte differentiation in the center of
these anlagen results in chondrocyte hypertrophy, expression of collagen type X and fibro‐
nectin, and subsequent mineralization of the surrounding matrix. Exteriorly located peri‐
chondrial cells differentiate into osteoblasts and stimulate the invasion of blood vessels that
initiate the conversion of the perichondrial layer into the periosteum where osteoblasts dif‐
ferentiate and secrete collagen type I and other bone matrix‐specific proteins. This collar will
eventually mineralize by means of intramembranous bone formation forming a bone collar
of cortical bone around the periphery of the tissue [29]. The combination of matrix minerali‐
zation and vascular invasion promotes the invasion of osteoblast precursor cells, osteoclasts,
blood vessel endothelial cells, and hematopoietic cells from the perichondrium into the hy‐
pertrophic cartilage. This results in the resorption of the hypertrophic cartilage, osteoblast
differentiation, and bone formation, and the hematopoietic and endothelial cells establish
the bone marrow stroma in what becomes the primary ossification center [34]. Eventually,
this primary ossification center expands and secondary ossification centers form at the distal
ends of the developing bone. This results in the development of epiphyseal growth‐plate
cartilage, responsible for the longitudinal growth of bones [35,36]. The epiphyseal growth
plate contains chondrocytes that are organized into structural and functional zones, each
with distinct gene expression patterns [37]. In the reserve zone, chondrocytes are spherical
with large amounts of matrix consisting of collagen type II and proteoglycans. This zone
transitions into a zone of chondrocyte proliferation, where chondrocytes appear discoid and
columnar. Elongation of the cartilaginous anlagen mainly occurs from the proliferation of
this zone. This zone transitions into the zone of maturation where chondrocytes become pre‐
hypertrophic. Here proliferation ceases; however, cell size increases as a result of growth. As
this zone progresses, chondrocytes continue to hypertrophy and secrete a collagen X‐rich
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matrix until eventually they undergo apoptosis leaving behind spaces for subsequent vascu‐
lar invasion and osteoblast differentiation and bone formation [29].
4. Cartilage and bone extracellular matrix
4.1. Cartilage ECM
The extracellular matrix of cartilage varies based on the type of cartilage. All cartilage types
have the aggregated proteoglycan formed by the glycosaminoglycan hyaluronic acid, the
chondroitin sulfate/keratan sulfate proteoglycan aggrecan, and link protein, as well as other
types of proteoglycans. Cartilage tissues vary in types of collagen present, and may contain
elastic fibers. The predominant fibrillar collagen in hyaline and elastic cartilage is type II
collagen, while in fibrocartilage the predominant fibrillar collagen is type I. Elastic cartilage
has elastic fibers comprising fibrillin and elastin [5]. Differences in the distribution of these
matrix molecules are observed in cartilage, with the pericellular matrix, territorial matrix, and
interterritorial matrix having distinct matrix compositions [8,38]. In addition, zones in articular
cartilage (superficial, intermediate, deep, and calcified) have a distinct organization of matrix.
The pericellular matrix of a chondrocyte contains proteins termed “matricellular proteins” to
distinguish them from matrix proteins present in other locations. A chondrocyte with its
pericellular matrix is termed a chondron [13] and the type of matrix determines the mecha‐
nophysical properties of the cartilage [12,39]. These major differences in the most prevalent
matrix molecules of the cartilage are not the only distinctions between the various matrices of
cartilages. Other fibrillar collagens present in cartilage include types III [40,41], V, and XI [41,
42]. Collagens IX, XII, and XIV (members of the FACIT group of collagens, or Fibril Associated
Collagens with Interrupted Triple helices) are present in cartilage matrix [42,43], as is type X
collagen during hypertrophy of cartilage in endochondral ossification [42]. Type IV, present
in basal laminae, is found in cartilage [44], as are type VI [8,42], type VII, type VIII, and type
XVIII collagen. Other proteins present in cartilage include fibronectin [45], thrombospondin
or COMP (cartilage oligomeric matrix protein) [46], SPARC or osteonectin, tenascin‐C, laminin
[44], and the subject of this chapter, CCNs [47]. Proteoglycans in cartilage consist predomi‐
nantly of the aggregated proteoglycan, with hyaluronic acid and aggrecan associated through
link protein. Other proteoglycans are observed including perlecan, decorin, lumican, fibro‐
modulin, syndecan, glypican, biglycan, and epiphycan; all may be present in cartilage in
addition to aggrecan [48]. The interaction of chondrocytes with their environment, and
particularly the matricellular molecules, can regulate proliferation, differentiation, shape
changes, apoptosis, and motility [38,47]. In addition to direct interaction of chondrocyte
cellular receptors, such as integrins, with matricellular proteins, the matrix of cartilage can
bind and release soluble molecules such as growth factors that regulate many cellular functions
[49].
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4.2. Bone ECM
Bone ECM is a composite material that provides the bulk, shape, and strength of bone tissue
through a combination of mineral, collagen, and non‐collagenous protein components.
However, bone ECM provides much more than just mechanical and structural support, due
to its role in the developmental patterning of bone and by providing a spatial context necessary
for regulating cellular behavior important for bone development and maintenance. ECM
proteins can signal through cell surface receptors on bone cells to regulate cell functions, and
factors contained within the ECM including growth factors, cytokines, chemokines, and
extracellular enzymes can also modulate the activity of bone cells and/or affect the ECM itself
[50]. Bone ECM contains numerous components (over 100 proteins) and various bone tissue
compartments (e.g., periosteum, marrow stroma, epiphyseal growth plate, etc.) have unique
ECM environments that play diverse roles in directing bone development through regulating
the differentiation process of mesenchymal stem cells and remodeling of bone through the
coupled activity of osteoclasts and osteoblasts [20]. Bone ECM can be generally broken down
into collagenous components that represent the majority of the ECM proteins and non‐
collagenous components including proteoglycans, glycosylated proteins, small‐integrin‐
binding, N‐glycosylated proteins (SIBLINGs), Gla‐containing proteins, numerous MMPs,
matricellular proteins, and cell‐associated proteins such as integrins and cadherins. Non‐
collagenous components have multifactorial roles in organizing the ECM, coordinating cell‐
cell and mineral‐matrix interactions, and regulating the mineralization process [51]. Here, we
summarize some of the key components of bone and cartilage ECM, describe their role in
various tissue compartments and their contributions for bone and cartilage development,
maintenance, and disease.
4.2.1. Collagenous proteins
Collagen type I—Collagen type I is by far the most abundant ECM protein found in the organic
component of the bone matrix accounting for roughly 90% and is the basic building block of
the bone matrix fiber network. It serves as a scaffolding substrate for mineralization and also
binds and orients other matrix proteins that nucleate the mineral depositions [51]. Collagen
type I is secreted by committed pre‐osteoblast cells and primarily determines the material
strength attributes of the skeleton, but is also involved in osteoblast lineage progression.
Collage type I can bind with integrins on pre‐osteoblasts to initiate signaling cascades that
activate Runx2 (a master transcriptional activator of osteoblast differentiation), which controls
the differentiation of osteoblasts and expression of other important bone‐specific ECM proteins
[e.g., osteopontin (OPN), bone sialoprotein (BSP), etc.] [52–54]. Human mutations in collagen
type I result in phenotypic features of osteogenesis imperfecta (OI) [55]. OI is characterized by
bone brittleness leading to a higher rate of fracture in patients with the disorder potentially
from thinner or osteoporotic‐like bone mass; however, the exact cause of these symptoms
remains an active area of investigation [20,56]. Animal models of the disease display brittle/
mechanically weak bones that possibly result from impaired or improper collagen minerali‐
zation [57] and defects in the microarchitecture of the bone structure [58,59]. More recently,
recessive forms of OI have confirmed that while the quantity and structure of type I collagen
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is critical to maintaining proper bone strength, posttranslational modification and assembly
of type I collagen into its normal lattice structure are key regulators of bone strength as well
[60].
Collagen type II—Collagen type II is the major structural protein in cartilage ECM (∼85%) and
the major collagen found in the growth plate during endochondral ossification [61]. It is
primarily found in the matrix secreted by the reserve zone chondrocytes. More than a hundred
human mutations of collagen type II have been identified; however, only heterozygous
mutations causing autosomal‐dominant phenotypes have been described to date due to
phenotypic variations and age‐dependent phenotypic transitions [62]. Type II collagen
mutations give rise to a spectrum of phenotypes predominantly affecting cartilage and bone
that range from severe disorders that are perinatally lethal to the milder conditions that are
recognized in the postnatal period and childhood. These can include skeletal abnormalities
(e.g., Stickler syndrome a.k.a. hereditary progressive arthro‐opthalmopathy) or chondrodys‐
plasias that are characterized by disproportionate short stature, eye abnormalities, cleft palate,
and hearing loss [62]. Mouse models where collagen II is deleted phenotypically resemble
human achondrogenesis type II and die immediately before or at birth and are smaller than
their littermates [63]. Long bones from these animals lack endochondral bone and the epiphy‐
seal growth plate and intervertebral discs are not developed [63,64]. Other mouse models with
mutations of collagen type II also display growth‐plate anomalies and chondrodysplasia [65];
some of these mice have similar phenotypes found in the human forms of the disease including
short bones, cleft palate, and respiratory failure [62,65].
Collagen type III and collagen type V—Collagen type III is a fibrillar collagen that is found in
extensible connective tissues such as vascular system, skin, gut, and lung, frequently in
association with type I collagen. Collagen type V is a minor fibrillar collagen found in skin,
tendons, and ligaments [66]. Both collagen type III and type V are found in bone and in trace
amounts and may play a role in regulating collagen diameter. Collagen type III is expressed
particularly during bone healing [51]. Human mutations in collagen type III and V are
associated with Ehlers‐Danlos syndrome, a disease characterized by defects in the structure,
production, or processing of collagen that leads to wide‐ranging symptoms in the digestive,
excretory, and particularly the cardiovascular systems [66]. Collagen type III mutations are
also associated with aortic and intracranial arterial aneurysms. Collagen type III null mice are
embryonic lethal, but analysis of null cells in culture or heterozygous mice suggests that type
III collagen may promote bone differentiation [67].
Collagen type VI is a major matricellular protein present in cartilage and most connective
tissues [8, 42, 68–70]. In cartilage, collagen type VI is present in the pericellular matrix and its
localization determines the boundary of this region [14]. Both integrins and the integral
membrane proteoglycan NG2 can bind to this collagen in cartilage [71–74]. Differentiated
chondrocytes express collagen type VI, while this expression is lost when chondrocytes
undergo dedifferentiation [75]. Human mutations of collagen type VI lead to a range of
disorders from a milder Bethlem myopathy to a more severe Ullrich muscular dystrophy
associated with muscle weakness [76]. Knockout mice lacking type VI collagen show altera‐
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tions in the skeleton, including less density of bone, delayed secondary ossification, and faster
development of osteoarthritis [70].
Collagen type X—type X collagen is found in cartilage, but due to its expression in hypertrophic
chondrocytes found in bone at the epiphyseal growth plate, it is important for endochondral
ossification [77–80]. Human mutations in COL10A1 lead to autosomal‐dominant Schmid
metaphyseal dysplasia [81]. Schmid metaphyseal dysplasia is phenotypically characterized by
long bones that are short and curved, with widened growth plates and metaphyses [82].
Interestingly, initial studies of collagen type X null mice showed no obvious abnormalities in
the development and growth of long bones [38]; however, phenotypic changes that in part
mimicked Schmid metaphyseal dysplasia were observed in a second, separate collagen X null
mouse line [83]. In these mice, the height of the resting zone of growth‐plate chondrocytes was
reduced and trabecular bone architecture was altered in the chondro‐osseous junction as well
as differences in the distribution and organization of growth‐plate ECM components [83]. In
transgenic mice models expressing dominant negative collagen type X, endochondral ossifi‐
cation was also effected displaying variable phenotypes [84,85]. In all of these models, the
hypertrophic zone of the growth plate was compressed and the degree of compression
correlated with phenotype severity [84,85]. Additionally, two other collagen X models the first
where mice express collagen X containing a deletion similar to one found in human Schmid
metaphyseal dysplasia patients and a second knock‐in mouse with a collagen X Asn617Lys
mutation displayed shortened limbs, consistent with a role in the epiphyseal growth plate [86–
88].
4.2.2. Non‐collagenous proteins
4.2.2.1. Proteoglycans
Bone ECM contains several proteoglycans that, other than collagens, represent the major
constituents of the bone ECM. Proteoglycans are macromolecules that contain a central core
protein and one or more acidic polysaccharide side chains (glycosaminoglycans) [51,89].
Proteoglycans exhibit diverse biological functions including cell proliferation, adhesion,
migration, and differentiation and act as structural components in tissue organization. They
can also interact with growth factors and cytokines, as well as with growth factor receptors,
and are implicated in cell signaling [90]. Bone ECM contains several classes of proteoglycans
that include small leucine‐rich proteoglycans (SLRP), aggrecan, heparin sulfate proteoglycans
(HSPGs), and hyaluronic acid [90].
Members of the SLRP family are composed of core proteins of leucine‐rich repeats that are
approximately 25 amino acids in length and represent the most abundant type of proteogly‐
cans in bone. Some of the most studied in bone include biglycan decorin, fibromodulin, and
lumican and these studies have demonstrated that SLRPs are involved in the structural
organization of the bone ECM and regulation of growth factor activity [90]. Biglycan is
distributed evenly throughout bone ECM [91] and can bind collagen type I and several
important bone growth factors such as transforming growth factor‐beta 1 (TGF‐β1) [89].
Biglycan null mice have reduced biomechanical bone strength [92] and fail to achieve peak
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bone mass due to a decrease in bone formation due to low osteoblast numbers and activity [92].
These mice also have an age‐related reduction in capacity to produce bone marrow stromal
cells (MSCs), reduced responses to TGF‐β1, reduced collagen synthesis, and relatively more
cellular apoptosis [93]. Additionally, quantitative variations in the range, mean, and distribu‐
tion profiles of the collagen fibril diameters were detected [93]. Decorin null mice have no
skeletal defect, with no major phenotypic changes in bone at macroscopic or histological levels;
however, changes in collagen fibril size and shape in bone have been observed. However,
decorin/biglycan double null mice have a more severe osteopenia than in biglycan‐deficient
mice, with earlier onset and severely reduced cortical and trabecular bone mass [93]. TGF‐β1‐
binding experiments demonstrated that it bounds to decorin with high affinity and that this
interaction may increase TGF‐β1‐receptor interaction to enhance its bioactivity [94]. Fibromo‐
dulin is a small keratan sulfate proteoglycan that is found in bone in a pericellular fashion near
late‐hypertrophic chondrocytes of the secondary ossification centers and in the growth plate
suggesting a role during endochondral ossification. Fibromodulin null mice have no apparent
skeletal phenotype but abnormal and fewer collagen fibril bundles in the tail than in wild‐type
animals [95,96]. Fibromodulin possesses the capacity for TGF‐β1 binding [97] and levels have
been correlated with decreased TGF‐β1 expression in multiple fetal and adult rodent models.
Recent studies suggest that fibromodulin coordinates temporospatial distribution of TGF‐β
ligands and receptors to modulate TGF‐β bioactivity [98]. Lumican is secreted specifically by
differentiating and mature osteoblasts and is a significant proteoglycan component of the bone
matrix, playing an essential role in the regulation of collagen fibril formation [99]. Lumican
null mice display altered collagen fibril structure [100]; however, no alteration in bone
structure was reported in these mice. Interestingly, double null lumican/fibromodulin mice
are smaller than their wild‐type littermates and display age‐dependent osteoarthritis [100].
Aggrecan is a large chondroitin sulfate proteoglycan and is the major proteoglycan component
of cartilage [101,102], but it is also expressed in developing bone tissue [103]. Human mutations
in aggrecan cause two types of spondyloepiphyseal dysplasia, an autosomal‐dominant
Kimberley type and autosomal‐recessive Aggrecan type, resulting in dwarfism, skeletal
abnormalities, and problems with vision and hearing, and an autosomal‐dominant familial
osteochondritis dissecans, which displays abnormal cartilage formation and joint issues. In
mice, a natural truncating mutation of aggrecan leads to an autosomal‐recessive cartilage
matrix‐deficiency syndrome with abnormal craniofacial structures, shortened limbs and tail,
and perinatal lethality [88]. In these mice, chondrocytes are disorganized and the amount of
hypertrophic chondrocytes is significantly reduced and expression of other ECM genes is
altered in the growth plates of these mutant mice [104].
HSPGs act as regulators of skeletal patterning, differentiation, growth, and homeostasis and
are a critical component of the hematopoietic stem cell niche within the growth plate and bone
marrow [105]. Studies suggest that osteoblast precursors and osteoblasts synthesize HSPGs
that both membrane‐ and matrix‐associated HSPG are found in bone tissue and may play an
important role in cell‐cell interactions between fibroblast‐like cells and osteoclast‐lineage cells
by interacting with heparin‐binding growth factors, growth factor receptors, and/or other
heparin‐binding adhesion molecules, such as fibronectin [90,106]. HSPGs act as co‐receptors
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for numerous signaling molecules, such as fibroblast growth factors (FGFs), vascular endo‐
thelial growth factor (VEGF), TGF‐β1, and TGF‐β2 in addition to various other cytokines
[107,108]. The binding of these signaling molecules to HSPGs can serve a variety of functional
purposes including immobilization of these factors or cytokines and/or protection against
proteolytic degradation, thereby affecting their biological availability and/or modulation of
their biological activity [90].
One example of the role that HSPGs can have on skeletal development can be seen with
perlecan. Perlecan is a large heparan sulfate/chondroitin sulfate proteoglycan and is a ubiq‐
uitous component of basement membranes and articular cartilage, and in bone it is present in
the extracellular matrix of the growth plate where it plays an important role in bone structure
[109–112]. Mutations in the human perlecan gene cause autosomal‐recessive skeletal disorders
including the severe and lethal Silverman‐Handmaker type characterized by a flat face,
disorganized growth plate, cleft palate, and death at birth to the milder Rolland‐Desbuquois
type dyssegmental dwarfism skeletal dysplasia [81]. Schwartz‐Jampel syndrome (myotonic
chondrodystrophy) is a milder, progressive disease as a result of reduced perlecan levels
characterized by abnormalities of the skeletal muscles (myotonic myopathy), bone dysplasia,
joint contractures, and/or growth delays resulting in dwarfism [81,113]. While most perlecan
null mice are embryonic lethal, surviving embryos have defects in skeletal development
starting at E14.5 with disorganized growth plates, reduced proliferation of chondrocytes,
reduced endochondral ossification, and reduced numbers of type II collagen fibrils [114,115].
The mice also die shortly after birth [114,115]. Additionally, it has been shown that perlecan
mediates binding and delivery of FGF‐2 to FGF receptors [116] and that it regulates VEGF
signaling and is essential for vascularization during endochondral bone formation [117].
Hyaluronic acid (hyaluronan) is a non‐sulfated linear polysaccharide present in the extracel‐
lular matrix of every vertebrate's tissue important for bone regeneration [118]. Large amounts
of hyaluronan are synthesized during bone formation and it plays a role in enhancing
chondrogenic and osteogenic differentiation potentials of mesenchymal stem cells [118] by
regulating expression of chondrogenic markers including sulfated glycosaminoglycans, SOX‐
9, aggrecan, and collagen type II and osteogenic markers alkaline phosphatase (ALP), osterix,
runx2, and collagen type I [119–121]. Additionally, hyaluronan synthase‐2 (Has2) knockout
mouse model demonstrates that it is important for spine development [122].
4.2.2.2. Glycosylated proteins (glycoproteins)
The majority of bone ECM proteins are modified posttranslationally with either N‐ or O‐linked
oligosaccharides. In addition, many glycoproteins found in bone ECM contain an arginine‐
glycine‐aspartic acid (RGD) sequence that facilitates integrin binding important for mechano‐
transduction [89]. Thus, glycoprotein proteins represent an ever‐growing group of bone ECM
proteins with diverse functions and thus we will only focus on some key proteins in this
chapter.
Osteonectin (SPARC, BM‐40) is a secreted, multifunctional calcium‐binding glycoprotein that
participates in tissue remodeling, morphogenesis, and bone mineralization and is secreted by
many different types of cells including osteoblasts [123,124]. Osteonectin can initiate miner‐
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alization by binding to type I collagen and synthetic hydroxyl apatite and mediating miner‐
alization of the type I collagen [123]. It has also been demonstrated that osteonectin can bind
growth factors and regulate their activity of growth factors including platelet‐derived growth
factor (PDGF), FGF, or (VEGF) [125,126]. It also regulates ECM and matrix metalloprotease
production [127,128]. Osteonectin also regulates cell proliferation, promotes osteoblastogen‐
esis [129], and it can stimulate angiogenesis [89]. Osteonectin‐deficient mice display decreased
bone remodeling with a marked negative bone balance that leads to osteopenia in older
animals [20]. Bone turnover is decreased as a result of both reduced osteoclast and osteoblast
surface with consequential development of low bone mass [20]. Expression of osteonectin in
the intervertebral disc decreases with age [130]; mice lacking osteonectin have disc herniations
[131] and may exhibit increased pain [132]. Osteonectin immunostaining is increased in
osteoarthritis in cartilage as compared to age‐matched controls [133], indicating a role for this
protein in the pathogenesis of osteoarthritis. Pseudoachondroplasia, which is related to
mutations in osteonectin, is caused by retention of this protein within the endoplasmic
reticulum. This disease is an autosomal‐dominant disorder that causes dwarfism [134].
Fibronectin is a high‐molecular weight glycoprotein dimer that is synthesized by numerous
connective tissues throughout the body and contains three alternative spliced domains.
Fibronectin is produced from a single gene but as a result of alternative splicing exists in vivo
in two forms: a soluble, circulating form known as plasma fibronectin that is synthesized in
hepatocytes and a cellular form produced by a number of cell types including osteoblasts and
gets incorporated into the bone matrix [135,136]. Fibronectin has been shown to bind to
extracellular matrix components including collagen, fibrin, and HSPGs [137]. Fibronectin can
also bind to 11 different integrins, six of which are expressed by osteoblasts; however, the
primary adhesion integrin that fibronectin binds to on osteoblasts remains an active area of
investigation [138]. It appears that fibronectin's key function is in the assembly of collagen as
fibronectin is critical for collagen polymerization and matrix integrity [139,140]. Osteoblasts
express fibronectin in multiple stages of their differentiation including during proliferation
and differentiation concurrently with collagen type I expression. FN null mice die in utero at
embryonic day 8.5, prior to skeletal development [141]. Studies using conditional null animals
found that while conditional deletion of fibronectin in differentiating osteoblasts failed to show
a decrease in fibronectin in the bone ECM, conditional deletion of fibronectin in the liver
showed a marked decrease in fibronectin content in bone ECM associated with a decreased
mineral‐to‐matrix ratio and changed biomechanical properties [138]. These studies suggest
that while osteoblast‐derived fibronectin affected osteoblast differentiation and function,
fibronectin found in bone ECM originates from the liver [138].
Thrombospondins are a family of ECM glycoproteins that consist of thrombospondins 1–5 and
can be divided into two subgroups: A, which contains thrombospondins 1 and 2, and B, which
contains thrombospondins 3–5 (a.k.a. cartilage oligomeric protein or COMP) [142]. We will
focus on thrombospondins 1, 2, and 5 (COMP) in this section. Thrombospondin 1 functions in
a wide variety of physiological functions including platelet aggregation, inflammatory
responses, and the regulation of angiogenesis during wound repair and tumor growth.
Thrombospondin 1 binds a variety of cell receptors including CD36, CD47 (integrin‐associated
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protein), numerous integrins, proteoglycans, and calcium [142–145]. Thrombospondin 2 has
similar physiological as thrombospondin 1, but it also plays a role in the assembly of connective
tissue ECM [142], while COMP is primarily expressed in cartilage and certain other connective
tissues and has roles in chondrocyte attachment, differentiation, and cartilage ECM assembly
[146]. Thrombospondins 1 and 2 can each bind latent TGF‐β, and unlike thrombospondin 2,
thrombospondin 1 can control TGF‐β bioactivity by releasing it from its latency complex [20].
Thrombospondin 1 null mice are reported to have minor trabecular bone abnormalities [147],
mild spine deformation [148], and mild growth‐plate cartilage disorganization [149] in
addition to enhanced angiogenesis [150]. Additionally, these models suggest that thrombo‐
spondin 1 plays a role in bone homeostasis, both in mediating bone matrix integrity and by
regulating OC formation as a matrix‐derived paracrine signaling molecules [151]. Conversely,
thrombospondin 2 null mice have an increase in MSC number, suggesting that it serves as an
inhibitor of MSC proliferation [152,153]. Human mutations in thrombospondin cause a
pseudoachondroplasia and a type of epiphyseal dysplasia [81]. COMP mutations cause a type
of pseudochondrodysplasia and an epiphyseal dysplasia [81,154,155]. Mice lacking this
protein tend to appear normal with regard to their skeleton [156], but do have issues with
wound healing [157,158]. COMP may affect cellular functions by affecting the interaction of
matrix and growth factors with chondrocytes [46]. Thrombospondins function primarily as
anti‐angiogenic proteins [159]. Thrombospondin is present in fibrocartilage of the interverte‐
bral disc, and lack of this protein causes disorganization of this region [160]. No disc herniation
was noted in these mice. Thrombospondins help to organize the growth plate [149]. In
osteoarthritis, inappropriate angiogenesis within the cartilage may cause changes in the
articular cartilage that lead to degradation of the matrix. Gene transfer of thrombospondin 1
using an adenoviral vector into knee joints suppressed osteoarthritis disease progression, with
concomitant reductions in new vessel growth and inflammatory cell infiltration [161].
Periostin is a disulfide‐linked, heparin‐binding N terminus‐glycosylated secreted protein that
appears to be essential for proper ECM synthesis, particularly with respect to collagen I
fibrillogenesis [162,163]. Expression of periostin occurs in many tissues including bone and
cartilage and under many pathologic states. It is expressed in osteoblasts and is present in the
intervertebral disc and its expression increases in degenerated human discs [130,164]. Overall,
the function of periostin in cartilage is not well understood [165]. Periostin expression is also
known to be prominent in fibrotic conditions, including subepithelial fibrosis in bronchial
asthma [166] and in bone marrow fibrosis [167]. Periostin null mice display severe growth
retardation, suggesting that periostin is essential for postnatal development. Histological
analysis of the periostin knockout mice demonstrated severe incisor enamel defects, perio‐
dontal disease, a lack of trabecular bone, cartilage, and cardiac valve defects; however, some
of these phenotypes might be secondary due to eating difficulties as a result of the lesions in
the periodontium [168].
Alkaline phosphatase is a glycoprotein enzyme that is found both bound to cell surfaces and
also within the mineralized matrix [51]. Human ALP is classified into four isoenzyme types,
tissue‐nonspecific (TNAP), intestinal, placenta, and germ cell of which the TNAP type is
ubiquitously expressed in many tissues, including bone and is the form implicated in its
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biomineralization [169]. Mineralization of cartilage, bone, and teeth occurs by a series of
physicochemical and biochemical processes that facilitate hydroxyapatite deposition (miner‐
alization) into collagen fibrils of the matrix [170] and/or within the lumen of chondrocyte and
osteoblast‐derived matrix vesicles [171,172] through hydroxylation of pyrophosphate provid‐
ing inorganic phosphates to promote mineralization [169]. Deactivating mutations in the
TNAP gene causes the inborn error of metabolism known as hypophosphatasia [173], charac‐
terized by poorly mineralized cartilage (rickets) and bones (osteomalacia), spontaneous bone
fractures, and elevated extra‐cellular inorganic pyrophosphate (PPi) concentrations [174,175].
TNAP null mice also display skeletal disease at approximately 10 days of age and featured
worsening rachitic changes, osteopenia, and fracture [176]. Histologically, these mice dis‐
played developmental arrest of chondrocyte differentiation in epiphyses and in growth plates
with diminished or absence of hypertrophic zones with progressive osteoidosis from defective
skeletal matrix mineralization [176].
4.2.2.3. Small‐integrin‐binding, N‐glycosylated proteins (SIBLINGs)
SIBLINGs are classified by the presence of the RGD sequence and large amounts of sialic acid
known as small‐integrin‐binding, N‐glycosylated proteins (SIBLINGs) [29]. SIBLINGs, along
with other matrix proteins, are thought to play a role in cell attachment facilitated by transient
or stable focal adhesions to ECM molecules mediated by cell surface receptors. They also play
a role in intracellular signaling. Although these SIBLINGs were initially only found in
mineralized tissue, many of them can now be found in other tissues [177,178]. Bone cells
synthesize at least five SIBLING members including OPN, BSP, dentin matrix protein‐1, dentin
sialoprotein, and matrix extracellular phosphoprotein. Here, we discuss on OPN and BSP.
Osteopontin (OPN; BSP‐1) is a highly negatively charged bone ECM protein that can undergo
extensive posttranslational modification mainly phosphorylation [179]. OPN is one of the most
extensively studied SIBLING proteins and has broad physiological and pathological functions
including development [180], bone remodeling [181], immune function [182], fibrosis [183],
and cancer [184]. It is expressed by a wide range of cells and promotes attachment, prolifera‐
tion, migration, chemotaxis, and apoptosis of macrophages, lymphocytes, osteoblasts, and a
range of tumor cells [185–187]. OPN binds calcium and is a key regulator of hydroxyapatite
nucleation and is produced by osteoblasts during their terminal differentiation prior to matrix
mineralization. OPN regulates bone mass and overall bone quality by minimizing strain‐
induced fatigue damage and microcrack propagation in bone [188]. In addition, it can also
mediate the attachment of osteoclasts and can affect the shape and size of hydroxyapatite
crystals in the bone ECM [189–191]. OPN can mediate signaling through integrins, for example,
it can bind to α4β1 integrin and trigger a cell type‐specific integrin‐mediated signaling cascade
[192]. OPN null mice showed no bone phenotype [193], but in stress situations, such as
oophorectomy, the mice do not develop osteoporosis [91]. Recent data confirm and extend this
observation that the skeleton of OPN null mice does not respond properly under stress
underlining the importance of OPN in bone metabolism [194,195]. However, other studies
have demonstrated that OPN null mice do have a bone phenotype also under physiological
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conditions [196–198]. More recent OPN null models demonstrate that while bone volume was
normal in young null animals, the volume and number of osteoclasts were increased, but that
osteoclasts from these mice have a lower resorptive capacity providing evidence for a role of
osteopontin in osteoclast activity [199].
BSP‐2 is a SIBLING glycoprotein and is expressed in chondrocytes, hypertrophic cartilage, and
in osteoblasts at the onset of mineralization and in osteoclasts [200]. BSP is highly expressed
at sites of primary bone formation [201], and it coincides with the initial formation of mem‐
branous and endochondral bone, the maximal level being reached during the formation of
embryonic bone [202]. BSP‐2 binds calcium; however, it does not nucleate the hydroxyl apatite
found in the bone ECM and BSP‐2 mediates cell attachment through interaction with vitro‐
nectin receptor [29]. BSP‐2 null mice are shorter than their wild type counterparts and display
a low level of bone remodeling, with both bone formation and mineralization severely
impairing in vivo and in vitro models [203]. These mice also have lower osteoclast numbers
and surfaces in vivo; osteoclast recruitment and activity in vitro were impaired and impair‐
ment of chondrocyte proliferation was suspected [203,204].
4.2.2.4. Gla‐containing proteins
Gla‐containing proteins refer to a group of endogenously made bone ECM proteins that
undergo vitamin K‐dependent gamma‐carboxylase modification. The dicarboxylic glutamyl
(gla) residues enhance calcium binding. The formation of gamma‐carboxy‐glutamic acid (Gla)
occurs via a unique posttranslational modification of specific peptide‐bound glutamate
residues, which is required for the biological activities of these proteins.
Osteocalcin (OCN) is one of the most abundant non‐collagenous proteins of the bone ECM. It
is produced by differentiated osteoblasts [205,206] and once transcribed undergoes posttrans‐
lational modifications within osteoblasts that include the carboxylation of three glutamic
residues [207]. Vitamin D stimulates osteocalcin transcription and vitamin K regulates the
carboxylation processes. Various growth factors, hormones, or cytokines can also modulate
osteocalcin production [206]. Osteocalcin is secreted by osteoblasts during active bone
formation and can bind with the mineralized bone ECM [207]; however, its exact role in bone
physiology remains an active area of investigation. Osteocalcin promotes the recruitment and
differentiation of circulating monocytes and osteoclast precursors, suggesting its role on
osteoblast‐osteoclast interaction and bone resorption [206–208] and other studies have shown
that osteoclast resorption is impaired in OCN null bone [208]. However, OCN null mice have
a higher bone mineral density without any change in bone resorption and mineralization [209].
Recently, tissue‐specific transgenic mice with osteoblast‐specific overexpression or reduced
OCN production suggested that OCN might have an important endocrine function for glucose
metabolism and lipid homeostasis [210,211].
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5. The CCN family
The CCN family makes up a group of six highly conserved, secreted, extracellular matrix‐
associated proteins that regulate diverse cellular functions, including skeletal development,
wound healing, fibrosis, and cancer. Originally named after the three identified members—
cysteine‐rich 61 (Cyr61, CCN1), connective tissue growth factor (CTGF, CCN2), and nephro‐
blastoma overexpressed (Nov, CCN3)—this family also includes the Wnt‐induced secreted
proteins 1–3 (i.e., WISP1/CCN4, WISP2/CCN5, and WISP3/CCN6). Members of the CCN
family share a unique and conserved modular structure and interact with and orchestrate
cellular responses to extracellular factors via direct binding to cell surface receptors, including
integrins, Notch1, neurotrophic tyrosine kinase receptor type 1 (TrkA), low‐density lipopro‐
tein receptor‐related proteins (LRPs), and HSPGs. CCN proteins can also mediate biological
functions by interacting with growth factors such as tumor growth factor beta (TGF‐β),
vascular endothelial growth factor, and bone morphogenetic proteins (BMPs) and by associ‐
ating with other ECM proteins including fibronectin and fibulin 1C. Through these interac‐
tions, CCN proteins serve both distinct and overlapping biological roles. Consequently,
deregulation of their expression or activities contributes to the pathobiology of several
diseases, many of which may arise when inflammation or tissue injury becomes chronic,
including vascular diseases, fibrosis, arthritis, and cancer.
5.1. Structure and function of CCN family members
CCN proteins are cysteine‐rich and share a modular structure (Modules I–IV), with an N‐
terminal secretory peptide followed by four conserved domains with sequence homologies to
insulin‐like growth factor‐binding proteins (IGFBPs), von Willebrand factor type C repeat
(VWC), thrombospondin type I repeat (TSP1), and a carboxyl‐terminal domain (CT) that
contains a cysteine‐knot motif [212]. The order of these modules has been strictly conserved
during evolution, suggesting that it is critically important for these proteins. Each module is
involved in protein binding and contains conserved hydrophobic, polar, and cysteine residues.
Module I shares 32% sequence homology with the N‐terminal cysteine‐rich regions of the IGF‐
binding proteins and contains a GCGC‐CXXC motif that is involved in IGF binding. Module
II includes a stretch of 70 amino acids with sequence identity to von Willebrand factor as well
as various thrombospondins, collagens, and mucins [212]. This domain has been shown to
mediate protein oligomerization [213]. Module III is a TSP1 repeat that contains the
WSXCSXXCG motif, which is thought to be implicated in the binding of sulfated glycoconju‐
gates and to be important for cell attachment [212,214]. The last module, Module IV, occurs at
the carboxy‐terminus of various extracellular proteins and is the least conserved of the four
domains at the nucleotide sequence level. It consists of several cysteine residues that adopt a
cysteine‐knot motif. This motif comprises a complex structure of two‐stranded β‐sheets that
lie face to face and are linked by three interlocking disulfide bridges [215] and occurs in TGF‐
β, PDGF, and nerve growth factor (NGF). It is critical for several of the biological functions of
CCN proteins and is thought to mediate dimerization and binding to cell surface receptors.
CCN5 is the only family member that lacks the CT domain [216]. A variable, central hinge
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region that is susceptible to proteolytic processing by MMPs and other proteases links the
amino‐terminus and carboxy‐terminus of these proteins, yielding two halves that bind distinct
cell surface receptors [217]. It is not clear whether the individual properties of each of the four
modules govern the biological properties of the CCN protein or if it is the combination of the
modules and other sequences within the protein that do so. However, all of the modules are
highly interactive with a number of other molecules, which include cell surface receptors, ECM
components, growth factors, and structural proteins [218].
5.2. Cell surface receptors mediating CCN functions in cartilage and bone
Despite the structural similarities that CCN proteins have to other protein domains as
described above, their interactions are unique because of their ability to bind extracellular
factors via their modular domains. CCN proteins have been shown to interact specifically with
cell surface receptors such as HSPGs, integrins, and LRPs, accounting for their ability to
regulate numerous cellular functions. CCN2, the most studied of the CCN family members,
shares common functionality with CCN1 with respect to interaction with integrins and HSPGs,
causing comparable biological effects. LRP1 is another common receptor shared by CCN2 and
CCN1; however, the target cell and biological consequence differ between the two [219,220].
Direct binding of CCN proteins to integrins present on cellular surface drives many of their
effects on cartilage and bone. Integrins comprise a large family of cell‐cell and cell‐matrix
receptors that signal both from the ECM to the cytoplasm and from the cell to the matrix (inside‐
out and outside‐in) [221]. Integrins are αβ heterodimers and can be present in a number of
configurations. The different combinations of α and β receptors define what ECM molecules
a cell interacts with. These receptors regulate many cellular functions such as proliferation,
differentiation, motility, and developmental processes among others [221]. A decrease in the
interaction of β integrins with matrix molecules is observed during the pathogenesis of
osteoarthritis, and thus the disruption of integrin‐matrix interaction causes cellular dysfunc‐
tion in cartilage [222]. Integrins that have been identified in cartilage include α5β1, αvβ3, αvβ5,
α6β1, α1β1, α2β1, α10β1, and α3β1. As is the case with matrix molecules, integrins are expressed
differentially in specific regions of cartilage and during development and pathogenesis.
Other matrix receptors are present in cartilage. One example is NG2, a transmembrane
proteoglycan in cartilage with the matricellular protein type VI collagen as its ligand [72–74].
NG2 interaction with type VI collagen may be an important interaction in determining the
progression of sarcomas [223]. Annexin V, or anchorin II, binds to type II collagen and is mainly
expressed in the superficial zone of articular cartilage [224]. CD44 binds to hyaluronic acid;
blocking of this receptor causes a loss of the matrix of cartilage [225].
As a matricellular protein, CCN2 also binds the fibronectin receptor (α5β1) and aggrecan, which
are major components of the ECM [226]. The interaction of α5β1 with fibronectin in cartilage
causes loss of the differentiated state [227]. Blocking of this integrin causes a loss of the
differentiation of pre‐hypertrophic chondrocytes [228]. A knockout mouse that has loss of β1
specifically in chondrocytes exhibits a disease similar to chondrodysplasia [222]. β? is the most
expressed integrin β subunit in osteoarthritic chondrocytes [229].
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CCN2 is induced by signaling from retinoids in cartilage in the growth plate [230]. CCN2
causes differentiation of the chondrocytes and is important for matrix deposition and signal‐
ing from cellular receptors [226,231]. Retinoids are important signaling molecules involved
in the cartilage becoming hypertrophic during endochondral ossification.
5.3. CCNs in chondrogenesis and osteogenesis
The CCN proteins appear to play a critical role in the establishment of the skeletal system and
have been shown to have positive and negative regulatory roles in skeletal development, as
demonstrated through cell culture experiments and animal models. Collectively, these studies
demonstrate that CCN proteins promote differentiation and proliferation of chondrocytes,
osteoblasts, and vascular endothelial cells, which are important in both endochondral and
intramembranous ossification.
Cartilage is first seen in the developing embryo in the areas that serve as templates for
endochondral ossification, as well as in Meckel's cartilage in the head area [1]. Both CCN1 and
CCN2 promote chondrogenic and osteoblastic differentiation [232,233]. CCNs can interact
with members of the TGF‐β and BMP family via the chordin‐like homology found in the VWC
domain, and modulate their binding affinity for their respective receptors [234]. CCN2 is
important during embryogenesis and bone formation, including during proliferation of
mesenchymal cells, their differentiation into chondrocytes, and condensation of these cells into
the cartilage model that will form bone [1,235]. CCN2 expression is highest in the vascular
tissue and the maturing chondrocytes of the embryo. TGF‐β, which induces CCN2, directs the
condensation of these cells and regulates secretion of other matricellular proteins such as
fibronectin [235]. Cells from CCN2 knockout mice do not undergo this condensation process
in vitro and have less synthesis of cartilage proteoglycans [236]. Neutralizing antibodies,
siRNA, and antisense oligonucleotides have all been used to demonstrate that reduced or
absence of CCN2 prevents condensation from occurring [1,235]. Overexpression of CCN2
causes an increase in the length and density of bones [237]. In vertebral bodies, downregulation
of CCN2 is necessary for chondrocyte differentiation [235]. These studies demonstrate that the
spatial and temporal regulation of CCNs is an important component of development.
Development of cartilage involves several different transcription factors, such as Sox 9, that
control this process, as well as growth factors that interact with cellular receptors to facilitate
various cellular functions [2]. Interaction with the extracellular matrix has been implicated in
development as well. Various epigenetic mechanisms and several different microRNAs also
are important in the development of cartilage [3,4].
BMPs are important during skeletogenesis [238] and are known to be regulated by CCN2 [234].
Expression of CCN2 is observed in both the perichondrium and the chondrocytes during
development [239]. BMPs play a role in the repair of cartilage as well as during development
[240]. BMP2 causes proliferation of chondrocytes during development, while BMP4 does not
[241]. CCN2 and CCN3 can bind BMP2 and abrogate its ability to promote chondrogenic and
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osteogenic differentiation [242,243], respectively, whereas CCN4 binding to BMP2 enhances
its function in osteogenesis [244]. CCN2 also binds BMP4 and blocks its signaling capabilities
[234]. This binding thus modulates the activity of BMP‐9. CCN2 also modulates the Wnt
pathway in Xenopus embryos by binding to LRP6 co‐receptor [245]. CCN2 expression in
chondrocytes is controlled by both Rac 1 and actin pathways that are mediated by TGF‐β/Smad
signaling. CCN4 is expressed in developing mesenchymal, pre‐osteoblastic, and cartilage cells
and is believed to regulate skeletal growth and repair [246]. A truncated form of CCN4,
WISP1v, has been shown to regulate the differentiation of chondrocytes toward endochondral
ossification [247].
Chondrocytes are usually considered quiescent in the adult, although this can change during
pathological processes such as osteoarthritis. Cartilage has very little capacity to regenerate,
even though progenitor cells are present in the adult [6]. This lack of repair ability causes a
number of disease issues as humans age, including the most prevalent form of degenerative
joint disease, osteoarthritis [7]. In adult skeletal systems, CCN2 is highly expressed in the
osteoblasts lining metaphyseal trabeculae and in osteogenic surfaces lining fracture calluses,
suggesting that its upregulation in these areas may contribute to bone growth and fracture
repair [248].
5.4. CCNs in cartilage and bone pathology
Several types of pathologies are observed in cartilage and bone. In cartilage, the most common
is osteoarthritis, which significantly increases as the population ages. Disorders of the inter‐
vertebral disc are observed as well, and also increase with aging. Wounding and subsequent
repair of cartilage occurs and can mimic the progression of osteoarthritis. Various types of
chondritis, or inflammation of cartilage, are observed in various regions of the body. Congen‐
ital defects in cartilage include conditions such as chondrodysplasia, an example of which
would be achondroplasia, causing dwarfism. Finally, chondromas or chondrosarcomas,
tumors that can either become or are cancer, can occur within this tissue.
5.4.1. Intervertebral disc
CCN2 is highly expressed in the cartilage present in the intervertebral disc, just as it is in other
types of cartilage. The intervertebral disc contains the nucleus pulposus, and this is surrounded
by the annulus fibrosus composed of fibrocartilage. The annulus fibrosus contains mainly the
fibrillar collagen type I, although type II collagen is present along the inner surface as in
reference [249]. Proper function of the annulus fibrosus is important in disc function, and lack
of intact matrix can lead to disc instability [249]. Herniation of the nucleus pulposus is
sometimes implicated as a cause of back pain [11] and increased expression of CCN2 can be
correlated with discs that are painful [250].
5.4.2. Osteoarthritis and cartilage wound healing
Osteoarthritis is the most common form of degenerative joint disease [7]. During the disease
process, chondrocytes undergo cell death due to lack of ability to renew, particularly with
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aging [251]. The initial degenerative changes that occur are termed chondropenia, although
this is not often identified as osteoarthritis [252]. Upregulation of the catabolic pathways
occurs, causing cartilage degradation, and alteration of the phenotype of the chondrocytes is
ultimately responsible for loss of articular cartilage [253]. Much of this change in cartilage
structure and function occurs via interactions with matrix and signaling from both matrix and
growth factors [254,255]. Initial disease presents with an upregulation of collagen type II
synthesis, and a change in collagen type from type II to types I and III [40,256]. A decrease in
aggrecan is observed during the pathogenesis of osteoarthritis, while other proteoglycans such
as decorin and fibromodulin are increased [257]. Aging causes decreased matrix deposition
subsequent to increases in degradation by MMPs as well, causing additional issues with tissue
integrity [255]. MMPs and aggrecanase are upregulated during osteoarthritis disease progres‐
sion [258] causing additional cartilage loss. These processes are very similar to what occurs
following an injury to cartilage and its subsequent repair [259].
CCN2 is increased in chondrocytes isolated from human osteoarthritis cartilage [260–262].
Increases in this matricellular protein can lead to fibrosis, and it is possible that mechanisms
used to deliver CCN2 to degenerating discs may cause some repair to occur [249] similar to
what is seen in an experimental model of osteoarthritis [263]. CCN3 has been shown to be
upregulated in an osteoarthritis mouse model [264] and in human osteoarthritis as well [265].
Mutation of CCN3 in mice causes a loss of normal joint function and disease that appears
similar to osteoarthritis in humans [266].
5.4.3. Chondromas/chondrosarcomas
A chondroma is a benign tumor of cartilage that may be present within bone and can cause
fractures due to its growth pattern. Normally, little is done with these tumors unless there is
a danger of fracture. Chondrosarcomas are cancerous tumors that can occur at any age, unlike
other sarcomas. These are refractory to treatment and can be highly metastatic. The expression
of CCNs can be correlated with chondrosarcoma grades and thus may be useful in clinical
identification of these tumors [267]. The same may be true for chondromas as well.
5.4.4. Osteosarcomas
Osteosarcoma is the most common type of cancer that develops in bone, occurring most
frequently in children and young adults. Most primary tumors develop in the areas of bone
that are growing rapidly such as near the ends of long bones surrounding the knee—the distal
femur or the proximal tibia. The proximal humerous is the next most common site, although
osteosarcoma can develop in any bone. Evidence suggests that osteosarcoma might originate
from mesenchymal cells with osteoblastic features [268,269]. CCN1 expression correlates with
poor prognosis of osteosarcoma and overexpression of CCN1 increases cell proliferation and
metastatic potential of tumor cell lines [270] and CCN1 knockdown reverses this phenomenon
[271]. In humans, CCN3 is associated with increased lung metastasis in osteosarcoma patients
[272] and CCN4 expression was shown to be higher in bone from osteosarcoma patients
compared to normal tissue [273].
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5.4.5. Ewing sarcoma
Ewing sarcoma is the second most common type of bone cancer that predominantly affects
children. CCN3 is expressed in approximately 30% of Ewing Sarcoma cases and its expression
correlates with lower survival [272]. Elevated CCN3 expression also correlated with recur‐
rences and metastases compared to primary tumors in a study that examined 170 human
Ewing sarcoma specimens by immunohistochemistry. In this same study, a low level of CCN3
expression was associated with improved patient prognosis [274].
5.4.6. Chondrodysplasias
Mutations in the major collagen present in hyaline and elastic cartilage, type II, cause several
chondrodysplasias [81]. Mutation of type XI collagen also causes skeletal issues due to issues
with the structure of the growth plate, in mice with this defect [275]. Mice lacking collagen IX
appear normal but have alterations in the cartilage forming the growth plate and ultimately
these mice develop osteoarthritis when older [276]. Mutations cause skeletal issues in humans
as well, as do mutations in type X collagen. Mice lacking collagen X have several phenotypes,
including no obvious changes, metaphyseal dysplasia, and death soon after birth [81,83,277].
5.4.7. CCNs in cartilage and bone pathophysiology
The role of CCNs in cartilage function involves several family members of this class of
matricellular proteins. CCN1‐6 have all been identified in cartilage matrix, and all CCN genes
have an increase in their expression in osteoarthritis or rheumatoid arthritis [265]. CCN3 is
integral to the proliferation of chondrocytes, while CCN1, CCN2, and CCN6 are involved in
later states of maturation, proliferation, and the calcification of cartilage matrix during
endochondral ossification. CCN4 and CCN5 also participate in the differentiation and
calcification of cartilage [231]. CCN2 causes proper bone strength, shape, and length, while
the counteraction by CCN3 regulates these structural processes.
CCN1 knockout mice die during development, making analysis of their skeleton difficult;
however, this protein causes proliferation of chondrocytes and secretion of matrix in vitro
[278]. CCN1 is present in chondrocytes in the proliferative and pre‐hypertrophic zones during
endochondral bone formation [278]. CCN1 signals through the WNT signaling pathway to
cause maturation of chondrocytes isolated from sternal cartilage, with overexpression of CCN1
causing damage to chondrocytes [279]. Induction of CCN1 by β‐catenin causes maturation of
chondrocytes, while overexpression using a cartilage‐specific promoter causes chondrodys‐
plasia [279]. CCN1 is decreased in expression during the differentiation of mesenchymal stem
cells into chondrocytes and osteoblasts, indicating that it may be important in the maintenance
of stem cells [280].
CCN2 promotes differentiation and proliferation of chondrocytes as well as osteoblasts (see
reference [47]). The presence of CCN2 is an important modulator of the deposition of cartilage
matrix. CCN2 also is a major factor in the induction of fibrosis [281]. This growth factor causes
secretion of collagen type II and can induce cells to proliferate and subsequently differentiate
[282]. Lack of CCN2 causes issues with bone growth due to lack of hypertrophic zone cartilage
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growth and loss of angiogenesis [283,284] and causes death immediately after birth due to
respiratory failure [239]. CCN2 binds several growth factors, including bone morphogenetic
proteins and TGF‐β, and can affect cartilage function in this manner [226].
Addition of CCN2 to damaged cartilage in rats can cause enhanced healing [263]. Although
exogenous administration of matrix metalloproteases can cause damage to cartilage similar to
osteoarthritis [285,286], the use of these inhibitors does not aid in the treatment of the disease
[287]. Overexpression of CCN2 using a col2a1 promoter caused reversal of some aging‐related
changes present in the articular cartilage of aged mice by enhancing matrix deposition and
proliferation of chondrocytes. In addition, changes characteristic of cartilage degeneration
were reversed, such as the expression of collagens I or X and the presence of MMPs 9 and 13
[288]. These mice also showed greater levels of matrix and faster ossification during endo‐
chondral bone growth [237].
CCN2 binds to receptor activator of NF‐kappa B (RANK) as seen by plasmon resonance
analysis, and enhances RANK signaling. This indicates its importance in the formation of
osteoclasts [289].
Fibroblast growth factor causes an increase in BMPs, and this binding causes repair of articular
cartilage defects. Different BMPs have differing effects on this repair, but overall BMP3 is an
important component during repair of articular cartilage [279].
CCN3 decreases proliferation in several different cell types [290]. CCN3 appears to be
downregulated by PTHrP [231], which is involved in the growth of bone. CCN3 may regulate
apoptosis under conditions of serum deprivation. The presence of this CCN decreased levels
of both proteoglycan and collagen, which may mimic the cartilage environment in which no
vascularization occurs and thus conditions are somewhat hypoxic [291]. Bone regeneration in
mice that lack CCN3 is enhanced [292]. Loss of CCN2 causes an increase in the expression of
CCN3 with a concomitant decrease in proliferation due to the presence of this matricellular
protein. This deletion also caused reduced differentiation of chondrocytes due to the upregu‐
lation of CCN3 [231]. Loss of CCN2 causes reductions in aggrecan and types II and X collagen
during development, a process which mimics the matrix loss that occurs with aging during
osteoarthritis development [226]. Overexpression of CCN2 has effects that counter these
reductions [288]. Overexpression of CCN4 caused an effect on cartilage differentiation by
changing the function of another growth factor, TGF‐β3. Mice that completely lacked CCN4
did repair surgical defects well, while mice that expressed CCN4 demonstrated some recovery
from this injury [293]. Lack of another member of the CCN family, CCN6, causes a disease in
humans that is a form of childhood arthritis, progressive pseudorheumatoid dysplasia [294].
The function of CCN6 in normal cartilage is not well understood, although its expression is
high in osteoarthritis [295].
CCN1 and CCN2 expression is elevated during fracture repair in the long bones throughout
the reparative phase of the callus, notably in proliferating chondrocytes and osteoblasts
[296,297]. Abrogation of CCN1 by antibodies inhibits bone fracture healing in mice [298].
Further, recombinant CCN2 protein promotes the repair of articular cartilage in a rat osteoar‐
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thritis model [263]. These studies suggest that CCN proteins may play important roles in the
homeostasis of bone and cartilage tissues.
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